Recombinant Human Leukemia Inhibitory Factor (rHuLIF, P15018, 3976) CAS#: 103-07-1816; ChemWhat Code: 1404494

Official Full Name Recombinant Human Leukemia Inhibitory Factor (rHuLIF)
Squence Squence of Recombinant Human Leukemia Inhibitory Factor
Amino Acid Sequence SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK LGCQLLGKYK QIIAVLAQAF
Synonyms Differentiation-stimulating Factor, D Factor, Melanoma-derived LPL Inhibitor, MLPLI
Accession Number P15018
GeneID 3976
Summary Leukemia inhibitory factor (LIF) is a member of Interleukin 6 family. This protein is mainly expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF is used in mouse embryonic stem cell culture, because that removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. It is also used in phase II clinical trial, which can assist embryo implantation in women who have failed to become pregnant despite assisted reproductive technologies (ART). Mature human LIF (180 a.a.) shares 78 %, 82 %, 91 %, 88 % and 87 % a.a. sequence identity with mouse, rat, canine, bovine, and porcine LIF, respectively.
Source Escherichia coli.
Molecular Weight Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 180 amino acids.
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by the dose-dependent proliferation of human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg.
Appearance Sterile filtered white lyophilized (freeze-dried) powder.
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Endotoxin Less than 1 EU/ug of rHuLIF as determined by LAL method.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-0.2 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
SDS-PAGE SDS-PAGE of Recombinant Human Leukemia Inhibitory Factor
Safety Data Sheet (SDS) Download Click to download
Technical Data Sheet (TDS) Download Click to download

Buy Reagent

ChemWhat 14044945ug/100ug/500ug (> 98 % by SDS-PAGE and HPLC)
No reagent supplier? Send quick inquiry to ChemWhat
Want to be listed here as a reagent supplier? (Paid service) Click here to contact ChemWhat

Approved Manufacturers

Want to be listed as an approved manufacturer (Requires approvement)? Please download and fill out this form and send back to [email protected]

Contact Us for Other Help

Contact us for other information or services Click here to contact ChemWhat